Merck Nemtabrutinib Discontinued: BELLWAVE CLL Program Ends After Safety Review

Merck nemtabrutinib discontinued infographic: three Phase 3 BELLWAVE CLL trials stopped

Merck has discontinued nemtabrutinib, its investigational non-covalent BTK inhibitor for chronic lymphocytic leukemia (CLL), ending the whole BELLWAVE clinical program after an external data monitoring committee concluded that benefits in the Phase 3 BELLWAVE-011 trial may not outweigh the risks. The company announced the decision after US markets closed on November 17, 2026. Merck has not released efficacy or safety figures, and says analyses are ongoing.

Key takeaways on Merck nemtabrutinib discontinued

  • BELLWAVE-011, a head-to-head Phase 3 against ibrutinib or acalabrutinib in untreated CLL/SLL, triggered the stop after an eDMC benefit-risk review.
  • Merck is also ending Phase 3 BELLWAVE-008 and BELLWAVE-010, so no late-stage nemtabrutinib study continues.
  • The specific safety or efficacy signal has not been disclosed. Results will be shared with the scientific community later.
  • The drug came from Merck’s roughly USD 2.7 billion acquisition of ArQule, announced in December 2019, and was the main asset in that deal.
  • Patients in the trials are advised to talk to their study team about next steps; approved BTK inhibitors and other CLL therapies remain available.

The three Phase 3 trials now ending

Nemtabrutinib was being tested across the CLL treatment pathway, from first line to relapsed disease. That breadth is why a single negative review led Merck to close everything at once.

TrialSettingDesignStatus
BELLWAVE-011 (NCT06136559)Untreated CLL/SLLNemtabrutinib vs investigator’s choice of ibrutinib or acalabrutinibStopped after eDMC review
BELLWAVE-008 (NCT05624554)Untreated CLL/SLL without TP53 aberrationsNemtabrutinib vs chemoimmunotherapyDiscontinued
BELLWAVE-010 (NCT05947851)Relapsed/refractory CLL/SLL after 1+ prior therapyNemtabrutinib + venetoclax vs venetoclax + rituximabDiscontinued

Merck’s head of global oncology clinical development, Dr. Marjorie Green, said the company had decided “to discontinue development of nemtabrutinib across the entire clinical program.” Earlier-stage studies, including BELLWAVE-001, -003, -015, -027 and waveLINE-006, are listed in the program history, though Merck’s release does not detail their individual status.

Why a head-to-head trial was a high bar

BELLWAVE-011 pitted nemtabrutinib directly against two established covalent BTK inhibitors. Ibrutinib (Imbruvica) and acalabrutinib (Calquence) are standard first-line options with years of follow-up, and zanubrutinib (Brukinsa) has added further competition. To win, a newcomer has to match their disease control while being at least as tolerable over treatment that can last many years.

Non-covalent BTK inhibitors bind the enzyme reversibly and were designed partly to keep working when the C481 mutation blocks covalent drugs. Lilly’s pirtobrutinib (Jaypirca) has already established that class in patients previously treated with a BTK inhibitor. Nemtabrutinib also inhibits several other kinases, a broader profile that some researchers saw as a possible advantage in resistant disease and others as a potential source of off-target side effects. Merck has not said which factor drove the committee’s view, so any link to the kinase profile is speculation at this stage.

What it means for Merck’s oncology business

For Merck, the cost is less about near-term revenue, since nemtabrutinib was not approved anywhere, and more about the pipeline it is building for the period after Keytruda’s key US patents expire later this decade. Hematology was a stated growth area, and the ArQule deal was Merck’s entry into BTK inhibition. By our calculation, the program has now run nearly seven years from the deal announcement without producing an approved product.

Any write-down will be disclosed in Merck’s financial filings; the November 17 release did not quantify one. Investors will watch whether Merck redeploys hematology spending toward other assets, such as its antibody-drug conjugates and bispecific antibodies, or toward further business development.

What it means for patients and the CLL field

  • Trial participants should not change treatment on their own; Merck has asked them to discuss options with their investigators.
  • Patients on approved BTK inhibitors are not affected. Nothing in Merck’s statement relates to ibrutinib, acalabrutinib, zanubrutinib or pirtobrutinib.
  • Researchers will want the full BELLWAVE-011 data. Whether the issue was weaker disease control, more toxicity, or both will matter for other reversible and multi-kinase BTK programs in development.

Market context

BTK inhibitors are among the largest drug classes in blood cancers, which is why so many companies have chased the space. According to Acumen Research and Consulting, the global lymphoma treatment market, which includes small lymphocytic lymphoma and drugs such as Imbruvica, was valued at USD 7.7 billion in 2021 and was forecast to reach USD 15.8 billion by 2030 at a CAGR of 8.4%, with Asia-Pacific the fastest-growing region. That report was last updated in 2022, so the figures are indicative rather than current. A crowded, well-served market raises the evidence bar for any new entrant.

What to watch next

  • Presentation of BELLWAVE-011 data at a medical meeting, likely including the reason for the benefit-risk call.
  • Any impairment charge in Merck’s next quarterly report.
  • Moves by other developers of reversible BTK inhibitors and BTK degraders, which may face investor questions about class safety.

For more pharma pipeline coverage, read our analysis of AstraZeneca’s Imfinzi and Padcev bladder cancer approval and other stories in Pharmaceuticals.

FAQ

Why did Merck stop nemtabrutinib?

An independent data monitoring committee reviewing the Phase 3 BELLWAVE-011 trial suggested the drug’s benefits may not outweigh its risks. Merck reviewed the totality of data and ended the full program. Specific findings have not been released.

What is nemtabrutinib?

An oral, reversible (non-covalent) BTK inhibitor, formerly known as ARQ 531, that Merck gained through its acquisition of ArQule. It was being developed for CLL, SLL and other blood cancers.

Does this affect people taking Imbruvica or Calquence?

No. The decision concerns only Merck’s investigational drug. Approved BTK inhibitors are unaffected.

What should BELLWAVE trial participants do?

Merck advises participants to speak with their study team and physician about next steps and alternative treatment options.

Sources: Merck press release, BELLWAVE program update (November 17, 2026); ClinicalTrials.gov records NCT06136559, NCT05624554 and NCT05947851. Market data: Acumen Research and Consulting. Not medical or investment advice. Last updated November 18, 2026.

Leave a Reply

Your email address will not be published. Required fields are marked *